Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads

Sengupta, Partho P.; Northfelt, Donald W.; Gentile, Federico; Zamorano, Jose L.; Khandheria, Buoy K.
February 2008
Mayo Clinic Proceedings;Feb2008, Vol. 83 Issue 2, p197
Academic Journal
Trastuzumab, a drug targeting human epidermal growth factor receptor 2, Improves survival rate In women with metastatic breast cancer. Symptomatic heart failure, a serious adverse effect of trastuzumab, occurs in 1% to 4% of patients treated with the antibody, whereas left ventricular ejection fraction declines substantially In 10% of patients. The prevalence of cardiotoxic effects of trastuzumab appears to Increase with exposure to anthracycilnes. Serial assessment of left ventricular function with 2. dimensional echocardiography or radionuclide ventriculography Is the most practical means of monitoring cardiotoxicity. Patients who develop cardiotoxicity while receiving trastuzumab therapy generally Improve once use of the agent Is discontinued.


Related Articles

  • PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Fujita, T.; Doihara, H.; Kawasaki, K.; Takabatake, D.; Takahashi, H.; Washio, K.; Tsukuda, K.; Ogasawara, Y.; Shimizu, N. // British Journal of Cancer;1/30/2006, Vol. 94 Issue 2, p247 

    Trastuzumab is the only HER2/neu-directed therapy to have received Food and Drug Administration approval for the treatment of patients with metastatic breast cancer. The efficacy of trastuzumab depends on the HER2/neu status of the tumour and the patient's prior treatment, but even when patients...

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. Baselga, Jos�; Cort�s, Javier; Kim, Sung-Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, Jos� Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Graham; Swain, Sandra M. // New England Journal of Medicine;1/12/2012, Vol. 366 Issue 2, p109 

    Background: The anti�human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized...

  • Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Kulkarni, S.; Reddy, K. B.; Esteva, F. J.; Moore, H. C. F.; Budd, G. T.; Tubbs, R. R. // Oncogene;3/4/2010, Vol. 29 Issue 9, p1339 

    Resistance to anti-HER2 (human epithelial growth factor receptor 2) trastuzumab therapy occurs commonly in HER2-positive breast cancer and involves overactivation of HER2 and/or AKT1. Using the model of trastuzumab-sensitive or trastuzumab-resistant HER2-positive cells with wild-type PTEN,...

  • Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice. YANHUI YANG; QIAN DENG; XIAOSHAN FENG; JUNJUN SUN // Molecular Medicine Reports;2015, Vol. 12 Issue 1, p746 

    The disulfiram/copper complex (DS/Cu) has been demonstrated to exert potent anti-tumor effects in various types of cancer. At present, whether DS/Cu has chemopreventive effects on breast cancer development remains to be fully elucidated. In the present study, using MMTV-erbB2 transgenic mice, it...

  • Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Shi, Yan-Xia; Tan, Yu-Ting; Yuan, Zhong-Yu; Wang, Shu-Sen; Peng, Rou-Jun; An, Xin; Cao, Ye; Jin, Ying; Cai, Xiu-Yu; Sun, Yue-Li; Teng, Xiao-Yu; Liu, Dong-Geng // Medical Oncology;Mar2012, Vol. 29 Issue 1, p39 

    Trastuzumab has been the standard treatment in first-line treatment of HER-2-positive advanced breast cancer (H2ABC). This study explored whether the delayed and repeated use of trastuzumab could influence overall survival (OS). A total of 128 patients with H2ABC who had received at least one...

  • Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu- Overexpressing Breast Cancer in Singapore. de Lima Lopes, Jr., Gilberto // BMC Cancer;2011, Vol. 11 Issue 1, p178 

    Background: Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in the adjuvant setting in Southeast Asia....

  • Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Peiró, G; Ortiz-Martínez, F; Gallardo, A; Pérez-Balaguer, A; Sánchez-Payá, J; Ponce, J J; Tibau, A; López-Vilaro, L; Escuin, D; Adrover, E; Barnadas, A; Lerma, E // British Journal of Cancer;8/1/2014, Vol. 111 Issue 4, p689 

    Background:Src is a non-receptor tyrosine kinase involved in signalling and crosstalk between growth-promoting pathways. We aim to investigate the relationship of active Src in response to trastuzumab of HER2-positive breast carcinomas.Methods:We selected 278 HER2-positive breast cancer patients...

  • Trastuzumab. Beedimani, R. S. // Indian Journal of Pharmacology;Dec2004, Vol. 36 Issue 6, p390 

    Provides information about the monoclonal antibody, trastuzumab. Approval of trastuzumab for the treatment of HER 2/neu positive metastatic breast cancer; Benefits of the antibody to breast cancer patients; Adverse effects of the antibody.

  • Trastuzumab improves survival, outcomes of HER2-positive breast cancer patients.  // Formulary;Mar2006, Vol. 41 Issue 3, p146 

    The article talks about trastuzumab as a treatment for advanced breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). The drug was in 1998 and was put into a test of efficacy and safety among breast cancer patients. It reveals that trastuzumab improved...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics